TSCAClinical Trialsbusinesswire

Tasca Therapeutics Doses First Patient in Phase 1/2 Dose Escalation and Expansion Trial Evaluating CP-383 in Advanced Solid Tumors

Sentiment:Positive (65)

Summary

(TSCA) CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #ClinicalTrials--Tasca Therapeutics has dosed the first patient in its Phase 1/2 dose escalation and expansion study of CP-383 in advanced solid tumors.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 16, 2025 by businesswire